PP
MRTX

Paloma Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Paloma Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,830
Closed -$780K – 2049
2021
Q2 		$780K Buy
+4,830
New +$776K 0.01% 773
2017
Q3 		– Sell
-56,650
Closed -$207K – 2527
2017
Q2 		$207K Buy
+56,650
New +$217K ﹤0.01% 1979

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Paloma Partners's MRTX Position: Q3 2021 in Review

Paloma Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 4,830 shares — an estimated $780K sold.

Paloma Partners first reported a position in MRTX in Q2 2017 and held it in 2 quarters. The position peaked at $780K in Q2 2021. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • Paloma Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Paloma Partners sold 4,830 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $780K.
  • Paloma Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Paloma Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $780K in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.